|Articles|March 16, 2021
HIC Analysis of Drug-to-Antibody Ratio
Author(s)Agilent Technologies, Inc.
This application note demonstrates the DAR determination of brentuximab vedotin using HIC. Excellent reproducibility was found with the Agilent 1290 Infinity II Bio LC.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
2
Implementing Automation and Flexible Design for Allogeneic Manufacturing
3
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
